UB Paderborn / Katalog / Suche / in CDI

Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis

American journal of physiology: Gastrointestinal and liver physiology, 2007-02, Vol.292 (2), p.G518-G525

2007

Link zum Volltext

Verfügbarkeit prüfen

MiR-155 modulates the inflammatory phenotype of intestinal myofibroblasts by targeting SOCS1 in ulcerative colitis

Experimental & molecular medicine, 2015-05, Vol.47 (5), p.e164-e164

2015

Link zum Volltext

Verfügbarkeit prüfen

Biliary Tree Diagnostics: Advances in Endoscopic Imaging and Tissue Sampling

Medicina (Kaunas, Lithuania), 2022-01, Vol.58 (1), p.135

2022

Link zum Volltext

Verfügbarkeit prüfen

Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients

Therapeutic advances in gastroenterology, 2021, Vol.14, p.1756284821999902-1756284821999902

2021

Link zum Volltext

Verfügbarkeit prüfen

Toward a potential association between eosinophilic esophagitis and Klinefelter syndrome: a case series and review of the literature

Therapeutic advances in gastroenterology, 2022-02, Vol.15, p.17562848221076888-17562848221076888

2022

Link zum Volltext

Verfügbarkeit prüfen

Extraintestinal Cancers in Inflammatory Bowel Disease: A Literature Review

Cancers, 2023-07, Vol.15 (15), p.3824

2023

Link zum Volltext

Verfügbarkeit prüfen

A framework for integrating BIM and IoT through open standards

Automation in construction, 2018-11, Vol.95, p.35-45

2018

Link zum Volltext

Verfügbarkeit prüfen

Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn's Disease

Journal of clinical medicine, 2024-03, Vol.13 (6), p.1539

2024

Link zum Volltext

Verfügbarkeit prüfen

A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study

Therapeutic advances in gastroenterology, 2021, Vol.14, p.175628482110314-17562848211031420

2021

Link zum Volltext

Verfügbarkeit prüfen

Fascin, an Actin-Bundling Protein, Modulates Colonic Epithelial Cell Invasiveness and Differentiation in Vitro

The American journal of pathology, 2003, Vol.162 (1), p.69-80

2003

Link zum Volltext

Verfügbarkeit prüfen

Cytoskeletal network in colon cancer: from genes to clinical application

The international journal of biochemistry & cell biology, 2004-05, Vol.36 (5), p.759-765

2004

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of different subtypes of serrated polyps and risk of synchronous advanced colorectal neoplasia in average-risk population undergoing first-time colonoscopy

Clinical and translational gastroenterology, 2012-01, Vol.3 (1), p.e6-e6

2012

Link zum Volltext

Verfügbarkeit prüfen

Should Patients With Inflammatory Bowel Disease Be Tested for Active COVID-19 Before Starting a Biological Treatment?

Gastroenterology (New York, N.Y. 1943), 2021-06, Vol.160 (7), p.2626-2627

2021

Link zum Volltext

Verfügbarkeit prüfen

Screening for active COVID-19 infection and immunization status prior to biologic therapy in IBD patients at the time of the pandemic outbreak

Digestive and liver disease, 2020-06, Vol.52 (6), p.604-605

2020

Link zum Volltext

Verfügbarkeit prüfen

Endoscopic ultrasound-guided transmural stenting for gallbladder drainage in high-risk patients with acute cholecystitis: a systematic review and pooled analysis

Surgical endoscopy, 2016-12, Vol.30 (12), p.5200-5208

2016

Link zum Volltext

Verfügbarkeit prüfen

E-Cadherin and the Cytoskeletal Network in Colorectal Cancer Development and Metastasis

Cell communication & adhesion, 2011-12, Vol.18 (6), p.133-143

2011

Link zum Volltext

Verfügbarkeit prüfen

Laryngeal Epithelial Defenses against Laryngopharyngeal Reflux: Investigations of E-Cadherin, Carbonic Anhydrase Isoenzyme III, and Pepsin

Annals of otology, rhinology & laryngology, 2005-12, Vol.114 (12), p.913-921

2005

Link zum Volltext

Verfügbarkeit prüfen

Reply Letter to “Oral butyrate modulates the gut microbiota in patients with inflammatory bowel disease, most likely by reversing proinflammatory metabolic reprogramming of colonocytes”

Neurogastroenterology and motility, 2021-01, Vol.33 (1), p.e14054-n/a

2021

Link zum Volltext

Verfügbarkeit prüfen

Reply to comment: Screening for active COVID-19 infection prior to biologic therapy in IBD patients: primum non nŏcēre

Digestive and liver disease, 2020-11, Vol.52 (11), p.1248-1249

2020

Link zum Volltext

Verfügbarkeit prüfen

Su1837 AN IBD NURSE-LED EDUCATIONAL PROGRAMME ON SAFETY AND EFFICACY OF ADJUVATED RECOMBINANT ZOSTER VACCINE CAN IMPROVE VACCINE UPTAKE IN IBD PATIENTS ON IMMUNOSUPPRESSIVE TREATMENT

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-836-S-837

2024

Link zum Volltext

Verfügbarkeit prüfen

Tu1874 IMMUNOGENICITY AND SAFETY OF ADJUVATED RECOMBINANT ZOSTER VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON DIFFERENT IMMUNOSUPPRESSIVE THERAPIES

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-1448-S-1448

2024

Link zum Volltext

Verfügbarkeit prüfen

Reply to comment: Asymptomatic screening for SARS COV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice

Digestive and liver disease, 2020-11, Vol.52 (11), p.1252-1253

2020

Link zum Volltext

Verfügbarkeit prüfen

Starting a Biologic Therapy in IBD Patients Amid COVID-19: Hold, Careful Monitoring, or Testing?

Journal of Crohn's and colitis, 2020-12, Vol.14 (12), p.1785-1785

2020

Link zum Volltext

Verfügbarkeit prüfen

Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease

Neurogastroenterology and motility, 2020-10, Vol.32 (10), p.e13914-n/a

2020

Link zum Volltext

Verfügbarkeit prüfen

Eosinophilic Esophagitis and Achalasia: Are We Putting All the Pieces Together?

The American journal of gastroenterology, 2021-08, Vol.116 (8), p.1759-1759

2021

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis

MiR-155 modulates the inflammatory phenotype of intestinal myofibroblasts by targeting SOCS1 in ulcerative colitis

Biliary Tree Diagnostics: Advances in Endoscopic Imaging and Tissue Sampling

Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients

Toward a potential association between eosinophilic esophagitis and Klinefelter syndrome: a case series and review of the literature

Extraintestinal Cancers in Inflammatory Bowel Disease: A Literature Review

A framework for integrating BIM and IoT through open standards

Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn's Disease

A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study

Fascin, an Actin-Bundling Protein, Modulates Colonic Epithelial Cell Invasiveness and Differentiation in Vitro

Cytoskeletal network in colon cancer: from genes to clinical application

Prevalence of different subtypes of serrated polyps and risk of synchronous advanced colorectal neoplasia in average-risk population undergoing first-time colonoscopy

Should Patients With Inflammatory Bowel Disease Be Tested for Active COVID-19 Before Starting a Biological Treatment?

Screening for active COVID-19 infection and immunization status prior to biologic therapy in IBD patients at the time of the pandemic outbreak

Endoscopic ultrasound-guided transmural stenting for gallbladder drainage in high-risk patients with acute cholecystitis: a systematic review and pooled analysis

E-Cadherin and the Cytoskeletal Network in Colorectal Cancer Development and Metastasis

Laryngeal Epithelial Defenses against Laryngopharyngeal Reflux: Investigations of E-Cadherin, Carbonic Anhydrase Isoenzyme III, and Pepsin

Reply Letter to “Oral butyrate modulates the gut microbiota in patients with inflammatory bowel disease, most likely by reversing proinflammatory metabolic reprogramming of colonocytes”

Reply to comment: Screening for active COVID-19 infection prior to biologic therapy in IBD patients: primum non nŏcēre

Su1837 AN IBD NURSE-LED EDUCATIONAL PROGRAMME ON SAFETY AND EFFICACY OF ADJUVATED RECOMBINANT ZOSTER VACCINE CAN IMPROVE VACCINE UPTAKE IN IBD PATIENTS ON IMMUNOSUPPRESSIVE TREATMENT

Tu1874 IMMUNOGENICITY AND SAFETY OF ADJUVATED RECOMBINANT ZOSTER VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON DIFFERENT IMMUNOSUPPRESSIVE THERAPIES

Reply to comment: Asymptomatic screening for SARS COV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice

Starting a Biologic Therapy in IBD Patients Amid COVID-19: Hold, Careful Monitoring, or Testing?

Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease

Eosinophilic Esophagitis and Achalasia: Are We Putting All the Pieces Together?

Suchergebnisse filtern